Cargando…
Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
BACKGROUND: High-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis...
Autores principales: | Detti, Beatrice, Scoccianti, Silvia, Teriaca, Maria Ausilia, Maragna, Virginia, Lorenzetti, Victoria, Lucidi, Sara, Bellini, Chiara, Greto, Daniela, Desideri, Isacco, Livi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370943/ https://www.ncbi.nlm.nih.gov/pubmed/34081269 http://dx.doi.org/10.1007/s11547-021-01381-5 |
Ejemplares similares
-
Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature
por: Detti, Beatrice, et al.
Publicado: (2022) -
Impact of COVID-19 on workload burden of a complex radiotherapy facility
por: Francolini, Giulio, et al.
Publicado: (2021) -
Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
por: Francolini, Giulio, et al.
Publicado: (2022) -
Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis
por: Francolini, Giulio, et al.
Publicado: (2022) -
ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement
por: De Felice, Francesca, et al.
Publicado: (2021)